Theresa L Werner1, Abhijit Ray2, John G Lamb2, Matthew VanBrocklin3, Kristin Hueftle4, Adam L Cohen1, Anna C Beck1, Saundra S Buys1, Donna L Dyess5, Thomas W Butler5, Theresa L Dumlao6, Leigh Neumayer7, Hung T Khong8. 1. Oncology Division, Department of Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT. 2. University of Utah, Huntsman Cancer Institute, Salt Lake City, UT. 3. Department of Surgery, University of Utah, Salt Lake City, UT. 4. Department of Medicine, University of Utah, Salt Lake City, UT. 5. Department of Surgery, University of South Alabama, Mitchell Cancer Institute, Mobile, AL. 6. Banner M.D. Anderson Cancer Center, Gilbert, AZ. 7. Oncology Division, Department of Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; Department of Surgery, University of Arizona, Tucson, AZ. 8. Oncology Division, Department of Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; Department of Surgery, University of South Alabama, Mitchell Cancer Institute, Mobile, AL; Department of Breast Oncology, Moffitt Cancer Center, Tampa, FL. Electronic address: hung.khong@moffitt.org.
Abstract
BACKGROUND: The aims of this study were to assess the safety and tolerability of nanoparticle albumin bound paclitaxel (nab-paclitaxel), doxorubicin, and cyclophosphamide as combination therapy for breast cancer patients in the neoadjuvant setting and to assess the overall clinical response and pathologic complete response (pCR). PATIENTS AND METHODS: Twenty-six women with newly diagnosed stage II to III histologically or cytologically proven adenocarcinoma of the breast with negative HER2 status were enrolled. Patients were treated with nab-paclitaxel 100 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 on day 1 and nab-paclitaxel 100 mg/m2 on day 8 in a 21-day cycle for 6 cycles total. RESULTS: Most adverse events attributed to treatment were decreased white blood cell count, neutropenia, anemia, thrombocytopenia, and lymphopenia with a median duration of 8 days. Fifteen of 23 (65.2%; 95% confidence interval [CI], 45.7%-84.6%) had a complete clinical response and 8 of 23 (34.7%; 95% CI, 15.2%-54.1%) had a partial clinical response for an overall clinical response rate of 100%. Thirteen of 23 patients (56.5%; 95% CI, 36.2%-76.7%) had a pCR. All 10 triple-negative breast cancer (TNBC) patients (100%) achieved a pCR. CONCLUSION: The regimen of nab-paclitaxel, doxorubicin, and cyclophosphamide chemotherapy was well tolerated and resulted in high clinical as well as pathologic responses, particularly in TNBC.
BACKGROUND: The aims of this study were to assess the safety and tolerability of nanoparticle albumin bound paclitaxel (nab-paclitaxel), doxorubicin, and cyclophosphamide as combination therapy for breast cancerpatients in the neoadjuvant setting and to assess the overall clinical response and pathologic complete response (pCR). PATIENTS AND METHODS: Twenty-six women with newly diagnosed stage II to III histologically or cytologically proven adenocarcinoma of the breast with negative HER2 status were enrolled. Patients were treated with nab-paclitaxel 100 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 on day 1 and nab-paclitaxel 100 mg/m2 on day 8 in a 21-day cycle for 6 cycles total. RESULTS: Most adverse events attributed to treatment were decreased white blood cell count, neutropenia, anemia, thrombocytopenia, and lymphopenia with a median duration of 8 days. Fifteen of 23 (65.2%; 95% confidence interval [CI], 45.7%-84.6%) had a complete clinical response and 8 of 23 (34.7%; 95% CI, 15.2%-54.1%) had a partial clinical response for an overall clinical response rate of 100%. Thirteen of 23 patients (56.5%; 95% CI, 36.2%-76.7%) had a pCR. All 10 triple-negative breast cancer (TNBC) patients (100%) achieved a pCR. CONCLUSION: The regimen of nab-paclitaxel, doxorubicin, and cyclophosphamide chemotherapy was well tolerated and resulted in high clinical as well as pathologic responses, particularly in TNBC.
Authors: Francisco Rodríguez; Pablo Caruana; Noa De la Fuente; Pía Español; María Gámez; Josep Balart; Elisa Llurba; Ramón Rovira; Raúl Ruiz; Cristina Martín-Lorente; José Luis Corchero; María Virtudes Céspedes Journal: Biomolecules Date: 2022-06-04
Authors: Miao Li; Meng Pan; Chengzhong You; Fengshu Zhao; Di Wu; Mei Guo; Hui Xu; Fangfang Shi; Danfeng Zheng; Jun Dou Journal: Breast Cancer Res Date: 2020-03-06 Impact factor: 6.466